News
Chemomab Reports New Peer-Reviewed Publication Reinforcing The Clinical Association Of Its CCL24 Target with Disease Severity and Mortality In Systemic Sclerosis
18 Apr 24
Biotech, News, Health Care, General
Chemomab Bagged New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
25 Mar 24
Government, News, Regulations
Oppenheimer Maintains Perform on Chemomab Therapeuticsto Perform
8 Mar 24
News, Analyst Ratings
Chemomab Therapeutics Q4 EPS $(0.26) Up From $(0.72) YoY
7 Mar 24
Earnings, News
Earnings Scheduled For March 7, 2024
7 Mar 24
Earnings
12 Health Care Stocks Moving In Thursday's Pre-Market Session
22 Feb 24
Movers
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
21 Feb 24
Movers
12 Health Care Stocks Moving In Tuesday's After-Market Session
20 Feb 24
Movers
What's Going On With Fibro-Inflammatory Disease Focused Chemomab Therapeutics On Tuesday?
20 Feb 24
Biotech, News, Health Care, Movers, General
Press releases
Chemomab to Host Virtual Key Opinion Leader Webinar on Primary Sclerosing Cholangitis on April 10, 2024
2 Apr 24
News, Health Care, Press Releases
Chemomab Awarded New European Patent for CM-101, Its First-in Class Monoclonal Antibody in Phase 2 Clinical Development for Primary Sclerosing Cholangitis
25 Mar 24
News, Legal, Press Releases, General
Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update
7 Mar 24
Earnings, Press Releases
Chemomab Therapeutics to Participate in Leerink Global BioPharma Conference
5 Mar 24
Press Releases
Chemomab Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update
14 Feb 24
Press Releases
Chemomab Therapeutics to Participate in Upcoming Investor Conferences
5 Feb 24
Press Releases
Chemomab Therapeutics Announces New Publication Reinforcing the Clinical Potential of Its CCL24-Neutralizing Antibody CM-101 in Primary Sclerosing Cholangitis
30 Jan 24
Press Releases